Medpace Holdings, Inc. (MEDP) Average EV/EBITDA Ratio
The current ev/ebitda ratio for Medpace Holdings, Inc. (MEDP) is 21.18x as of Wednesday, June 17, 2026, shown against its trailing averages.
Average EV/EBITDA Ratio Chart
MEDP EV/EBITDA Ratio Averages
EV/EBITDA RATIO CURRENT
21.18x
EV/EBITDA RATIO TTM
26.03x
EV/EBITDA RATIO 3Y
25.80x
EV/EBITDA RATIO 5Y
25.61x
EV/EBITDA RATIO 10Y
22.53x
EV/EBITDA RATIO 15Y
22.53x
EV/EBITDA RATIO 20Y
22.53x
About Medpace Holdings, Inc.
Medpace Holdings, Inc., founded in Cincinnati, Ohio, in 1992, functions as a contract research organization (CRO) delivering clinical development and research services. The company assists pharmaceutical, biotechnology, and medical device clients throughout North America, Europe, and Asia. Its comprehensive suite of offerings covers the entire product lifecycle, from initial Phase I trials through to Phase IV post-market surveillance. Medpace's services include designing development programs, coordinating central laboratory functions, managing projects, navigating regulatory processes, overseeing clinical trials, handling data management and analytics, ensuring pharmacovigilance, aiding with new drug application submissions, and providing ongoing post-marketing clinical support. Furthermore, the company offers specialized bio-analytical laboratory testing, conducts clinical human pharmacology studies, provides imaging services, and delivers expert electrocardiography (ECG) reading for clinical research.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- August James Troendle